TEVA PHARMACEUTICAL INDUSTRIES LTD. 2024-2025 Proxy Voting Records

Description as filed by funds: ELECTION OF DIRECTORS: Chen Lichtenstein - to serve until Teva's 2027 Annual Meeting

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Chen Lichtenstein”): 654,450,171 for, 135,306,461 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The shareholders elected to appoint the following person to the Board, to serve until Teva's 2027 annual meeting of shareholders, as follows: The shareholders elected to appoint the following persons to the Board, to serve until Teva's 2028 annual meeting of shareholders, as follows:”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 82 asset managers below reported 153,011,345 for, 32,666 abstained, 900 unknown.

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

Description as filed by funds: ELECTION OF DIRECTORS: Amir Elstein - to serve until Teva's 2028 Annual Meeting

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Amir Elstein”): 628,249,902 for, 172,959,185 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The shareholders elected to appoint the following person to the Board, to serve until Teva's 2027 annual meeting of shareholders, as follows: The shareholders elected to appoint the following persons to the Board, to serve until Teva's 2028 annual meeting of shareholders, as follows:”
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 82 asset managers below reported 150,568,242 for, 2,443,103 against, 32,666 abstained, 900 unknown.

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

Description as filed by funds: ELECTION OF DIRECTORS: Dr. Tal Zaks to serve until Teva's 2028 Annual Meeting

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Dr. Tal Zaks”): 653,460,760 for, 136,254,343 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The shareholders elected to appoint the following person to the Board, to serve until Teva's 2027 annual meeting of shareholders, as follows: The shareholders elected to appoint the following persons to the Board, to serve until Teva's 2028 annual meeting of shareholders, as follows:”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 82 asset managers below reported 152,924,249 for, 87,096 against, 32,666 abstained, 900 unknown.

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

Description as filed by funds: ELECTION OF DIRECTORS: Dr. Perry D. Nisen to serve until Teva's 2028 Annual Meeting

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Dr. Perry D. Nisen”): 644,697,802 for, 145,078,739 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The shareholders elected to appoint the following person to the Board, to serve until Teva's 2027 annual meeting of shareholders, as follows: The shareholders elected to appoint the following persons to the Board, to serve until Teva's 2028 annual meeting of shareholders, as follows:”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 82 asset managers below reported 152,924,249 for, 87,096 against, 32,666 abstained, 900 unknown.

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

Description as filed by funds: ELECTION OF DIRECTORS: Roberto A. Mignone to serve until Teva's 2028 Annual Meeting]

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Roberto A. Mignone”): 652,577,603 for, 137,177,350 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) The shareholders elected to appoint the following person to the Board, to serve until Teva's 2027 annual meeting of shareholders, as follows: The shareholders elected to appoint the following persons to the Board, to serve until Teva's 2028 annual meeting of shareholders, as follows:”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 82 asset managers below reported 152,913,361 for, 97,984 against, 32,666 abstained, 900 unknown.

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

Description as filed by funds: To approve the compensation to be provided to Teva's non- executive chairman of the board

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“(5B) The shareholders approved an amendment to the compensation to be provided to Teva's non-executive Chairman of the Board, as follows:”): 772,020,910 for, 29,129,637 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(5B) The shareholders approved an amendment to the compensation to be provided to Teva's non-executive Chairman of the Board, as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 79 managers: 154,823,672 for, 32,666 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 16 managers: 29,501,576 for, 7,457,294 against, 900 unknown.

Description as filed by funds: To approve the compensation to be provided to Teva's non- employee directors

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“(5A) The shareholders approved an amendment to the compensation to be provided to Teva's non-employee Directors, as follows:”): 773,824,912 for, 27,111,172 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(5A) The shareholders approved an amendment to the compensation to be provided to Teva's non-employee Directors, as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 79 managers: 154,823,672 for, 32,666 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 15 managers: 29,499,818 for, 7,457,294 against, 900 unknown.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 79 managers: 154,262,386 for, 34,800 against, 32,666 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 4 managers: 2,129,056 for, 900 unknown.

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“2. On a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting”): 688,836,027 for, 99,207,637 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) The shareholders approved, on a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting, as follows:”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 80 managers: 154,619,905 for, 135,053 against, 101,464 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 466 managers: 480,434,274 for, 35,288,498 against, 2,000,934 abstained, 37,918 not voted, 900 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve an amended compensation policy with respect to the terms of office and employment of Teva's Executive Officers and Directors

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 78 managers: 152,449,506 for, 34,800 against, 32,666 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 15 managers: 55,998,008 for, 7,457,372 against, 900 unknown.

Description as filed by funds: TO APPOINT KESSELMAN & KESSELMAN, A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIONAL LTD., AS TEVA'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM UNTIL TEVA'S 2026 ANNUAL MEETING OF SHAREHOLDERS

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“6. The appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2026 annual meeting of shareholders”): 820,210,234 for, 35,027,740 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(6) The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2026 annual meeting of shareholders, as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 154,161,534 for, 136,205 against, 32,666 abstained, 900 unknown.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.